Connecticut's Healthcare Benchmark Initiative: Data Analytics Workgroup Meeting

February 7, 2024



Meeting Agenda

- 1. Welcome and Roll Call
- 2. Approval of the November 15th Meeting Minutes Vote
- 3. Developing a Cost Growth Driver Measure Set
- 4. Follow-Up Analyses to Assess the Representativeness of APCD Data
- 5. Public Comment
- 6. Wrap-up



Welcome and Roll Call



Vote: Approval of the November 15th Meeting Minutes



Developing a Cost Growth Driver Measure Set



Background

- OHS has set a 2024 goal to develop a cost growth driver measure set for annual public reporting.
- To date, the analyses that OHS has updated on an annual basis have included an assessment of commercial market:
 - trends in per member per month (PMPM) spending by service category, and
 - the relative roles of changes in payment rates and utilization on trend.
- We will briefly review the latest iteration of this analysis (presented to the Steering Committee in late January) and then discuss what should be the measure set for future annual reporting.

Office *of* Health Strategy

Measured Population

- Connecticut residents, 2017-2022
- Commercial (fully insured, and State employees and retirees)
 - Self-insured not included
- Exclusions
 - Non-Connecticut residents
 - Secondary payers
 - Denied, reversed, and non-primary claim lines
 - Claim lines with negative payment or cost-sharing
 - Payments made six months or longer after the service year
- <u>Reminder</u>: non-claims-based payments and pharmacy rebates are not in the APCD

Office *of* Health Strategy

Commercial Medical and Retail Pharmacy Spending, 2017-2022

		Com	mercial M	Average	2021 -				
Davor							annual	2022	Total
Payer	2017	2018	2019	2020	2021	2022	change	change	change (%)
							(%)	(%)	
All-payer	\$369	\$397	\$418	\$381	\$460	\$489	6.2%	6.5%	32.7%

		Commer	cial Retail	Average	2021 -	Total			
Payer							annual	2022	change
i dyci	2017	2018	2019	2020	2021	2022	change	change	(%)
							(%)	(%)	(/0)
All-payer	\$78	\$78	\$77	\$78	\$85	\$96	4.4%	13.2%	23.1%



Commercial Spending Breakdown by Service Category, 2017-2022

Somico Cotogomy		Percentage of Spending									
Service Category	2017	2018	2019	2020	2021	2022					
Total PMPM	\$447	\$475	\$495	\$459	\$545	\$585					
Inpatient	18.1%	18.4%	18.6%	19.0%	17.9%	17.3%					
Outpatient*	27.9%	28.8%	30.1%	29.5%	30.5%	31.4%					
Outpatient hospital	26.1%	27.0%	28.1%	27.5%	28.1%	28.9%					
Outpatient ASC	1.8%	1.9%	2.0%	2.0%	2.3%	2.5%					
Professional	33.3%	33.2%	32.7%	31.3%	32.1%	31.4%					
Retail Pharmacy**	17.5%	16.4%	15.6%	17.0%	15.6%	16.4%					
Other***	2.8%	2.8%	2.8%	3.0%	3.7%	3.2%					

* Outpatient includes outpatient hospital and ambulatory surgical center (ASC) spending.

** Retail pharmacy includes all members with pharmacy coverage, with or without medical coverage.

*** "Other" services include DME, home health, hospice, ICF and SNF claims.

Source: APCD



Service Category Contributions to Spending Growth, 2017-2022

Payer			Cumulative				
Гаусі	2017	2018	2019	2020	2021	2022	change
All-payer	\$447	\$475	\$495	\$459	\$545	\$585	+\$139

Contribution to Cumulative Commercial PMPM Growth by Service Category									
Inpatient	Outpatient	Professional	Retail Pharmacy	Other					
15%	43%	25%	13%	4%					



Impact of Price vs Utilization on Spending Growth: Commercial Medical and Retail Pharmacy

	Commercial Medical											
							Avg. Annual					
Measure	2017	2018	2019	2020	2021	2022	Change (%)					
Spending (PMPM)	\$369	\$397	\$418	\$381	\$460	\$489	6.2%					
Price (PPU)	\$365	\$399	\$417	\$405	\$386	\$433	3.7%					
Utilization (UPK)	12114	11936	12043	11315	14280	13560	2.9%					

	Commercial Retail Pharmacy											
							Avg. Annual					
Measure	2017	2018	2019	2020	2021	2022	Change (%)					
Spending (PMPM)	\$78	\$78	\$77	\$78	\$85	\$96	4.4%					
Price (PPU)	\$77	\$77	\$77	\$85	\$90	\$98	4.9%					
Utilization (UPK)	12985	13027	13055	12869	13397	14159	1.8%					

Impact of Price vs Utilization on Spending Growth: Commercial Inpatient and Outpatient Hospital

	Commercial Inpatient Hospital										
							Avg. Annual				
Measure	2017	2018	2019	2020	2021	2022	Change (%)				
Spending (PMPM)	\$81	\$87	\$92	\$87	\$97	\$101	4.8%				
Price (PPU)	\$20,784	\$25,102	\$27,853	\$29,879	\$31,341	\$32,957	9.8%				
Utilization (UPK)	47	42	40	35	37	37	-4.4%				

	Commercial Outpatient Hospital											
Measure	2017	2018	2019	2020	2021	2022	Avg. Annual Change (%)					
Spending (PMPM)	\$117	\$128	\$139	\$126	\$153	\$169	8.2%					
Price (PPU)	\$1086	\$1259	\$1369	\$1213	\$949	\$1361	7.0%					
Utilization (UPK)	1288	1221	1218	1250	1935	1492	5.8%					

Impact of Price vs Utilization on Spending Growth: Commercial Professional

	Commercial Professional											
							Avg. Annual					
Measure	2017	2018	2019	2020	2021	2022	Change (%)					
Spending (PMPM)	\$149	\$158	\$162	\$144	\$175	\$184	4.8%					
Price (PPU)	\$179	\$192	\$197	\$193	\$201	\$211	3.4%					
Utilization (UPK)	10018	9871	9875	8919	10462	10476	1.3%					



Ē

Impact of Price vs Utilization on Spending Growth: Commercial ED and Radiology

	Commercial Emergency Department											
Measure	2017	2018	2019	2020	2021	2022	Avg. Annual Change (%)					
Spending												
(per member)	\$173	\$199	\$239	\$202	\$245	\$290	11.9%					
Price (PPU)	\$778	\$978	\$1183	\$1272	\$1283	\$1299	11.3%					
Utilization (UPK)	7.2	6.6	6.5	5.3	6.4	7.4	1.8%					

	Commercial Radiology											
Measure	2017	2018	2019	2020	2021	2022	Avg. Annual Change (%)					
Spending												
(per member)	\$262	\$260	\$257	\$220	\$261	\$277	1.7%					
Price (PPU)	\$446	\$425	\$407	\$402	\$383	\$384	-2.9%					
Utilization (UPK)	18	19	20	18	22	24	6.1%					

Ę

Impact of Price vs Utilization on Spending Growth: Commercial Administered Drugs and Lab/Pathology

Commercial Administered Drugs							
Measure	2017	2018	2019	2020	2021	2022	Avg. Annual Change (%)
Spending	2017	2010	2017				change (70)
(per member)	\$113	\$136	\$155	\$157	\$158	\$177	9.6%
Price (PPU)	\$188	\$227	\$242	\$275	\$213	\$220	4.3%
Utilization (UPK)	19	19	21	19	25	27	7.3%

Commercial Lab/Pathology							
Measure	2017	2018	2019	2020	2021	2022	Avg. Annual Change (%)
Spending							
(per member)	\$121	\$120	\$119	\$98	\$131	\$131	2.8%
Price (PPU)	\$40	\$43	\$42	\$43	\$42	\$42	1.0%
Utilization (UPK)	97	91	88	77	105	103	2.5%

Cost Growth Driver Measure Set Proposal (1 of 2)

- OHS has considered historical OHS reporting practices, plus Dr. Gifford's interest in adding measurement of payment variation, to develop a first-draft proposal for Workgroup consideration.
 - The first draft is preliminary; it was created for Workgroup discussion purposes.
- We'll review that proposal on the next slide, and then seek your ideas for modifications to the draft proposal.



Cost Growth Driver Measure Set Proposal (2 of 2)

- 1. Per capita spending trends at the state and market levels, stratified by service category and by the relative contributions of changes in payment rates and service utilization.
- 2. Per capita hospital spending growth at the state level by service sub-category, and by hospital by service sub-category.
- **3.** Per capita pharmacy spending growth (retail and medical, separated and combined) by drug class and by drug, and by brand and generic.
- 4. Variation in payment, and payment trend, per service unit and by "market basket" for a) hospital services, and b) high volume/high spend medical specialties.
- **5.** Per capita spending and payment per service unit comparison to external benchmarks, e.g., Medicare, other states.



Discussion

- What do members think of the proposed analyses?
- What other analyses do members think should be included in this "cost growth driver measure set"?



Follow-Up Analyses to Assess the Representativeness of the All-Payer Claims Database (APCD)



Background (1 of 3)

- Performance against the Cost Growth Benchmark is assessed using aggregate data for all covered lives provided by insurers and public payers. However, these data do not allow for analysis of what is driving health care cost growth. For that, OHS must use more granular (claims and/or encounter data) from the state's APCD.
- The APCD does not include the commercial self-insured market (apart from the state employee health plan), which makes up over half the commercial market. For this reason, hospitals have argued to OHS that the APCD data are not representative of commercial market spending.



Background (2 of 3)

- To assess whether the APCD is representative of the total commercial market, OHS performed an analysis to assess whether the inpatient hospital DRGs identified as representing a) the most discharges, and b) the most spending according to APCD data were the same as those identified through analysis of the hospital inpatient discharge database (HIDD).
 - The hospital inpatient discharge database contains *all* discharges, including discharges for patients with fully insured and self-insured commercial coverage.



Background (3 of 3)

- OHS compared the top 10 DRGs in terms of total commercial discharges and the top 10 DRGs in terms of total commercial spending identified using APCD data to those identified using HIDD data.
 - The analysis of spending compared *allowed amounts* (APCD) to *charges* (HIDD).
- This analysis was presented to this Work Group during its last meeting. Members requested the following additional information, which we will share with you now:
 - Including the proportion of total volume and spending that the top 10 services in each analysis represent for the APCD vs the HIDD
 - Repeating the analysis after excluding maternity/newborn services



Highest Volume Services (Discharges) Statewide, 2021

DRG	Inpatient Service	Volume Rank (APCD)	Volume Rank (HIDD)
807	Vaginal Delivery without Sterilization or D&C w/o Major Complication	#1	#2
795	Normal Newborn	#2	#1
794	Neonate with Other Significant Problems	#3	#3
885	Psychoses	#4	#5
788	Cesarean Section without Sterilization w/o Major Complication	#5	#4
177	Respiratory Infections and Inflammations with Major Complication	#6	#6
897	Alcohol Drug Abuse or Dependence w/o Rehabilitation Therapy w/o Major Complication	#7	#16
806	Vaginal Delivery without Sterilization or D&C with Complication	#8	#8
871	Septicemia or Severe Sepsis w/o MV > 96 Hours with Major Complication	#9	#7
787	Cesarean Section without Sterilization w/ Complication	#10	#9
Propor	tion of total commercial discharges these 10 services represent in each database	41.2%	41.3%
			CONNECTICUT Office <i>of</i> Health Strategy



Highest Spend Services Statewide, 2021

DRG	Inpatient Service	Spending Rank (APCD)	Spending Rank (HIDD)
177	Respiratory Infections and Inflammations with Major Complication	#1	#3
807	Vaginal Delivery without Sterilization or D&C w/o Major Complication	#2	#1
885	Psychoses	#3	#2
871	Septicemia or Severe Sepsis w/o MV > 96 Hours with Major Complication	#4	#4
790	Extreme Immaturity or Respiratory Distress Syndrome, Neonate	#5	#7
788	Cesarean Section without Sterilization w/o Major Complication	#6	#5
3	ECMO or Tracheostomy with MV >96 Hours or PDX Except Face, Mouth and Neck with Major OR Procedure	#7	#6
455	Combined Anterior and Posterior Spinal Fusion w/o Complication	#8	#14
621	OR Procedures for Obesity w/o Complication	#9	#19
219	Cardiac Valve and Other Major Cardiothoracic Procedures w/o Cardiac Catheterization with Major Complication	#10	#21
Propo	rtion of total commercial allowed amounts (APCD) / charges (HIDD) these 10 services represent in each database	24.5%	21.5%
			Office of Health Strategy

Highest Volume Services (Discharges) Statewide, 2021

*excluding maternity/newborn services

DRG	Inpatient Service	Volume Rank (APCD)	Volume Rank (HIDD)
885	Psychoses	#1	#1
177	Respiratory Infections and Inflammations with Major Complication	#2	#2
897	Alcohol Drug Abuse or Dependence w/o Rehabilitation Therapy w/o Major Complication	#3	#9
871	Septicemia or Severe Sepsis w/o MV > 96 Hours with Major Complication	#4	#3
621	OR Procedures for Obesity w/o Complication	#5	#6
392	Esophagitis Gastroenteritis and Miscellaneous Digestive Disorders w/o Major Complication	#6	#5
470	Chronic Kidney Disease	#7	#7
872	Septicemia or Severe Sepsis w/o MV < 96 Hours w/o Major Complication	#8	#8
247	Intestinal Obstruction	#9	#10
330	Major Small and Large Bowel Procedures with Complication	#10	#14
Propor	tion of total commercial discharges these 10 services represent in each database	18.7%	16.0% ²⁵

Highest Spend Services Statewide, 2021

*excluding maternity/newborn services

DRG	Inpatient Service	Spending Rank (APCD)	Spending Rank (HIDD)
177	Respiratory Infections and Inflammations with Major Complication	#1	#2
885	Psychoses	#2	#1
871	Septicemia or Severe Sepsis w/o MV > 96 Hours with Major Complication	#3	#3
3	ECMO or Tracheostomy with MV >96 Hours or PDX Except Face, Mouth and Neck with Major OR Procedure	#4	#4
455	Combined Anterior and Posterior Spinal Fusion w/o Complication	#5	#9
621	OR Procedures for Obesity w/o Complication	#6	#12
219	Cardiac Valve and Other Major Cardiothoracic Procedures w/o Cardiac Catheterization with Major Complication	#7	#14
454	Combined Anterior and Posterior Spinal Fusion with Complication	#8	#10
25	Craniotomy and Endovascular Intracranial Procedures with Major Complication	#9	#16
853	Infections and Parasitic Diseases with OR Procedures with Complication	#10	#5
Prop	ortion of total commercial allowed amounts (APCD) / charges (HIDD) these 10 services represent in each database	20.2%	19.1% 26

Discussion



Public Comment



Wrap-Up



Wrap-up

- Workgroup meetings will be held every other month on the first Wednesday, contingent on OHS having sufficient content to present the Workgroup for discussion.
- The next meeting is scheduled for Wednesday April 3rd at 2 pm.

